The US Food and Drug Administration (FDA) has approved givinostat (Duvyzat) for treatment of Duchenne muscular dystrophy (DMD) in patients aged 6 years or older. Givinostat, […]

TOPLINE: Hospitalization for influenza is linked to a greater risk for subsequent neurologic disorders including migraine, stroke, or epilepsy than hospitalization for COVID-19, results of a […]

TOPLINE: Low low-density lipoprotein (LDL) cholesterol is associated with an increased risk of bleeding within 3 months of a major ischemic stroke (MIS) or high-risk transient […]

Use of statin drugs was associated with improved mortality in older nursing home residents, regardless of dementia status, a new study showed. The study is among […]

When added to corticosteroids, treatment with the investigational agent givinostat led to statistically and clinical meaningful benefits in ambulatory children with Duchenne muscular dystrophy (DMD) compared […]

The US Food and Drug Administration (FDA) has approved the first gene therapy for metachromatic leukodystrophy (MLD), a rare and debilitating genetic disease affecting the brain […]

Black patients are nearly 50% less likely to receive genetic evaluation and testing for neurologic disorders compared with White patients, a new study showed. Investigators found […]

Three genetically targeted drugs for Duchenne muscular dystrophy (DMD) — eteplirsen, golodirsen, and casimersen — cost the US health care system more than $3 billion between […]

Epilepsy was linked to a significantly increased the risk for hospitalization and death from COVID-19 early in the pandemic, while healthcare utilization rates in this patient […]